New insights into the regulation of HDL metabolism and reverse cholesterol transport.
The metabolism of high-density lipoproteins (HDL), which are inversely related to risk of atherosclerotic cardiovascular disease, involves a complex interplay of factors regulating HDL synthesis, intravascular remodeling, and catabolism. The individual lipid and apolipoprotein components of HDL are mostly assembled after secretion, are frequently exchanged with or transferred to other lipoproteins, are actively remodeled within the plasma compartment, and are often cleared separately from one another. HDL is believed to play a key role in the process of reverse cholesterol transport (RCT), in which it promotes the efflux of excess cholesterol from peripheral tissues and returns it to the liver for biliary excretion. This review will emphasize 3 major evolving themes regarding HDL metabolism and RCT. The first theme is that HDL is a universal plasma acceptor lipoprotein for cholesterol efflux from not only peripheral tissues but also hepatocytes, which are a major source of cholesterol efflux to HDL. Furthermore, although efflux of cholesterol from macrophages represents only a tiny fraction of overall cellular cholesterol efflux, it is the most important with regard to atherosclerosis, suggesting that it be specifically termed macrophage RCT. The second theme is the critical role that intravascular remodeling of HDL by lipid transfer factors, lipases, cell surface receptors, and non-HDL lipoproteins play in determining the ultimate metabolic fate of HDL and plasma HDL-c concentrations. The third theme is the growing appreciation that insulin resistance underlies the majority of cases of low HDL-c in humans and the mechanisms by which insulin resistance influences HDL metabolism. Progress in our understanding of HDL metabolism and macrophage reverse cholesterol transport will increase the likelihood of developing novel therapies to raise plasma HDL concentrations and promote macrophage RCT and in proving that these new therapeutic interventions prevent or cause regression of atherosclerosis in humans.
Lewis
Gary F
GF
Department of Medicine and Physiology, University of Toronto, Canada. gary.lewis@uhn.on.ca
Rader
Daniel J
DJ
D000070998:ATP Binding Cassette Transporter, Subfamily G, Member 1; D018528:ATP-Binding Cassette Transporters / Q000502:physiology; D000818:Animals; D016632:Apolipoprotein A-I / Q000096:biosynthesis; D001692:Biological Transport; D002784:Cholesterol / Q000378:metabolism*; D002788:Cholesterol Esters / Q000378:metabolism; D004268:DNA-Binding Proteins / Q000502:physiology; D006801:Humans; D015228:Hypertriglyceridemia / Q000378:metabolism; D007333:Insulin Resistance; D008049:Lipase / Q000502:physiology; D008066:Lipolysis; D008071:Lipoprotein Lipase / Q000502:physiology; D008075:Lipoproteins, HDL / Q000378:metabolism*; D000071518:Liver X Receptors; D008565:Membrane Proteins / Q000502:physiology; D057093:Orphan Nuclear Receptors; D049294:Phospholipid Transfer Proteins / Q000502:physiology; D018160:Receptors, Cytoplasmic and Nuclear / Q000502:physiology
C419353:ABCG1 protein, human; D000070998:ATP Binding Cassette Transporter, Subfamily G, Member 1; D018528:ATP-Binding Cassette Transporters; D016632:Apolipoprotein A-I; D002788:Cholesterol Esters; D004268:DNA-Binding Proteins; C504173:LIPC protein, human; D008075:Lipoproteins, HDL; D000071518:Liver X Receptors; D008565:Membrane Proteins; D057093:Orphan Nuclear Receptors; D049294:Phospholipid Transfer Proteins; D018160:Receptors, Cytoplasmic and Nuclear; D002784:Cholesterol; D008049:Lipase; D008071:Lipoprotein Lipase